Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

Presentation

Biodegradable-Polymer Synergy vs Durable-Polymer Xience for PCI in Clinical Practice

August 14, 2019

Presentation TCT Abstracts Posters 2018

Comparison of neointimal hyperplasia between the thin strut MiStent with microcrystalline sirolimus and the durable polimer coated everolimus-eluting Xience stent: 6- and 24-months results of the DESSOLVE III OCT sub-study

Presenter: Krzysztof Milewski

September 25, 2018

Presentation

Three-Year Clinical Outcome of Patients With Bifurcation Treatment With Second-Generation Resolute and Xience V Stents

Presenter: M.K. Lam

October 31, 2014

Presentation TCT 2014

Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience ? Results from CENTURY II___

Presenter: Kazushige Kadota

September 16, 2014

Presentation TCT 2013

TCT-21. Prognosis of Clinical Outcomes in Chinese Patients Receiving XIENCE V Everolimus-Eluting Stent with Baseline and Residual Syntax Score: One-Year Results from the...

Presenter: Yuejin Yang

October 29, 2013

Presentation TCT 2013

TCT-16. Incidence, mechanisms and outcome of longitudinal stent deformation (LSD) associated with Element, Resolute, Biomatrix and Xience stents: angiographic and case-by-case...

Presenter: Samer Arnous

October 29, 2013

Presentation TCT 2013

From Xience V to Prime to Xpedition: Stent Design Evolution and Clinical Trial Results (SPIRIT and Others)

Presenter: James Hermiller Jr

October 28, 2013

Presentation TCT 2013

Latest Results from ABSORB Extend: Comparison with Xience

Presenter: Bernard Chevalier

October 27, 2013

Presentation

Elutax Paclitaxel-Eluting Balloon (PEB) Followed by BMS Compared with Xience V DES for Coronary De Novo Stenosis

Presenter: F. Liistro

October 14, 2013

Presentation

A Clinical and Angiographic Study of the Xience V EES in the Treatment of Multivessel CAD

Presenter: Flavio Ribichini

September 23, 2013

Presentation ACC 2013

Three-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents

Presenter: Ian T. Meredith

March 09, 2013

Presentation TCT 2013

Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow-up data...

Presenter: Peter Smits, A. J. van Boven, Mariano Valdes, Antonio Serra, Jean-Jacques Goy, V. Voudris, Ramiro Trillo, J. M. Vazquez, Peter den Heijer, Ton Slagboom, A.G. Vuillomenet

January 31, 2013

Presentation TCT 2013

Clinical Outcome in Chinese Patients with Long Lesion or Small Vessel / Multivessel Disease Receiving XIENCE V Everolimus-Eluting Stent: Early Results from the SEEDS Study

Presenter: Bo Xu, Yuejin Yang, Yaling Han, Bao Li, Qiang Liu, Guoying Zhu, Junyu Cui, Lang Li, Shuzheng Lu

January 31, 2013

Presentation

Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V vs. Zotarolimus-Eluting Resolute Stents in Real-World Practice

Presenter: K. W. Park

December 25, 2012

Presentation TCT 2012

TCT-45. Long Term Safety and Effectiveness of XIENCE V® Everolimus Eluting Coronary Stent System in Real-world Population: Three-Year Clinical Outcomes from the XIENCE V® USA Study

Presenter: James Hermiller Jr

October 23, 2012

Presentation TCT Russia 2012

Lessons from Pooled Data with Xience Everolimus-Eluting Stents

Presenter: Gregg W. Stone

April 26, 2012

Presentation ACC 2012

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

Presenter: Gregg Stone

March 28, 2012

Presentation

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute vs. Everolimus-Eluting Xience V in Real-World Patients: TWENTE

Presenter: C. Von Birgelen

February 20, 2012

Presentation TCT 2012

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Presenter: David R. Rutledge, James B. Hermiller, Jin Wang, Mitchell W. Krucoff

January 03, 2012

Presentation TCT 2012

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Presenter: Israel M. Barbash, Rebecca Torgusson, Itsik Ben-Dor, Gabriel Maluenda, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

January 03, 2012

Advertisement

Biodegradable-Polymer Synergy vs Durable-Polymer Xience for PCI in Clinical Practice

Comparison of neointimal hyperplasia between the thin strut MiStent with microcrystalline sirolimus and the durable polimer coated everolimus-eluting Xience stent: 6- and 24-months results of the DESSOLVE III OCT sub-study

Three-Year Clinical Outcome of Patients With Bifurcation Treatment With Second-Generation Resolute and Xience V Stents

Clinical Outcomes of Patients With High Risk Acute Coronary Syndrome Treated With a New Generation Drug-Eluting Stent, Ultimaster compared with Xience ? Results from CENTURY II___

TCT-21. Prognosis of Clinical Outcomes in Chinese Patients Receiving XIENCE V Everolimus-Eluting Stent with Baseline and Residual Syntax Score: One-Year Results from the...

TCT-16. Incidence, mechanisms and outcome of longitudinal stent deformation (LSD) associated with Element, Resolute, Biomatrix and Xience stents: angiographic and case-by-case...

From Xience V to Prime to Xpedition: Stent Design Evolution and Clinical Trial Results (SPIRIT and Others)

Latest Results from ABSORB Extend: Comparison with Xience

Elutax Paclitaxel-Eluting Balloon (PEB) Followed by BMS Compared with Xience V DES for Coronary De Novo Stenosis

A Clinical and Angiographic Study of the Xience V EES in the Treatment of Multivessel CAD

Three-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents

Randomized comparison of Biolimus-eluting (Nobori) and Everolimus-eluting (Xience/Promus) stents in patients with multivessel coronary artery disease: 12-month follow-up data...

Clinical Outcome in Chinese Patients with Long Lesion or Small Vessel / Multivessel Disease Receiving XIENCE V Everolimus-Eluting Stent: Early Results from the SEEDS Study

Safety and Efficacy of Second-Generation Everolimus-Eluting Xience V vs. Zotarolimus-Eluting Resolute Stents in Real-World Practice

TCT-45. Long Term Safety and Effectiveness of XIENCE V® Everolimus Eluting Coronary Stent System in Real-world Population: Three-Year Clinical Outcomes from the XIENCE V® USA Study

Lessons from Pooled Data with Xience Everolimus-Eluting Stents

Two-Year Results of the PLATINUM Randomized Trial Comparing Platinum Chromium PROMUS Element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents in De Novo Coronary Artery Lesions

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute vs. Everolimus-Eluting Xience V in Real-World Patients: TWENTE

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content